Literature DB >> 14667516

Frequency, clinical presentation and evolution of renal oncocytomas: multicentric experience from a European database.

Leo Romis1, Luca Cindolo, Jean Jacques Patard, Giovanni Messina, Vincenzo Altieri, Laurent Salomon, Claude Clement Abbou, Dominique Chopin, Bernard Lobel, Alexandre de La Taille.   

Abstract

OBJECTIVES: To understand the clinical behavior of renal oncocytoma in a retrospective analysis of a European multicentric nephrectomies database.
METHODS: The records of 891 patients who underwent surgical resection of renal neoplasm were reviewed. Relevant clinical and pathological data for each patient were retrieved in a database.
RESULTS: Thirty-two (3.6%) cases of renal oncocytoma were identified. Twenty patients (62.5%) were asymptomatic. No case of lymphatic invasion or metastatic disease, nor any evidence of vascular or fat tissue invasion was found. Thirty-one cases (96%) exhibited low mitotic activity. In one case the presence of renal clear cell carcinoma (diameter: 1.5cm) was found. After a median follow-up of 42 months, 87.5% of patients were alive with no evidence of tumor, while 9.3% of patients had died for non-malignant causes. One patient had not treated the tumor surgically and was disease-free at a 27-month follow-up.
CONCLUSIONS: Renal oncocytoma is a benign neoplasm, characterized by slow growth and excellent prognosis after surgery. Nephron sparing techniques may be adequate for tumor removal.

Entities:  

Mesh:

Year:  2004        PMID: 14667516     DOI: 10.1016/j.eururo.2003.08.008

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  18 in total

1.  The impact of germline BHD mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytoma.

Authors:  Ronald S Boris; Jihane Benhammou; Maria Merino; Peter A Pinto; W Marston Linehan; Gennady Bratslavsky
Journal:  J Urol       Date:  2011-04-15       Impact factor: 7.450

Review 2.  Renal oncocytoma, yet another tumour that does not fit in the dualistic benign/malignant paradigm?

Authors:  Th Van der Kwast; B Perez-Ordoñez
Journal:  J Clin Pathol       Date:  2007-06       Impact factor: 3.411

3.  Can renal oncocytoma be differentiated from its renal mimics? The utility of anti-mitochondrial, caveolin 1, CD63 and cytokeratin 14 antibodies in the differential diagnosis.

Authors:  Ozgur Mete; Isin Kilicaslan; Mine G Gulluoglu; Veli Uysal
Journal:  Virchows Arch       Date:  2005-08-17       Impact factor: 4.064

Review 4.  Gender differences in benign renal masses.

Authors:  Julian Mauermann; Michela de Martino; Matthias Waldert; Andrea Haitel; Hans Christoph Klingler; Mesut Remzi; Tobias Klatte
Journal:  World J Urol       Date:  2013-02-16       Impact factor: 4.226

5.  Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma.

Authors:  B Amend; J Hennenlotter; M Scharpf; S Kruck; U Kuehs; E Senger; A S Merseburger; M A Kuczyk; K D Sievert; A Stenzl; J Bedke
Journal:  World J Urol       Date:  2011-08-07       Impact factor: 4.226

Review 6.  Oncocytic mania: a review of oncocytic lesions throughout the body.

Authors:  F Guaraldi; G Zang; A P Dackiw; P Caturegli
Journal:  J Endocrinol Invest       Date:  2011-02-07       Impact factor: 4.256

7.  Case report of a symptomatic giant renal oncocytoma.

Authors:  Sarfraz Ahmad; Rustom Manecksha; Brian D Hayes; Ronald Grainger
Journal:  Int J Surg Case Rep       Date:  2011-03-03

8.  Renal oncocytoma: A report of two cases and review of the literature.

Authors:  Yuantao Wang; Y U Hu; Xiuyu Zhai; Weigang Wang; Biao Dong; Honglan Zhou
Journal:  Oncol Lett       Date:  2016-05-17       Impact factor: 2.967

Review 9.  [The diagnostic and therapeutic challenges of bilateral renal oncocytosis : Illustrative case presentations and a review of the literature].

Authors:  M Janssen; M Eckerl; J Moersler; M Rotter; M May; C Gilfrich
Journal:  Urologe A       Date:  2016-07       Impact factor: 0.639

Review 10.  [What can/should be treated in kidney tumors and when].

Authors:  C M Sommer; D F Vollherbst; G M Richter; H U Kauczor; P L Pereira
Journal:  Radiologe       Date:  2017-02       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.